GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » EV-to-EBIT

ESSA Pharma (ESSA Pharma) EV-to-EBIT : -4.93 (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ESSA Pharma's Enterprise Value is $127.22 Mil. ESSA Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.80 Mil. Therefore, ESSA Pharma's EV-to-EBIT for today is -4.93.

The historical rank and industry rank for ESSA Pharma's EV-to-EBIT or its related term are showing as below:

EPIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -45.48   Med: 0   Max: 3
Current: -4.93

During the past 10 years, the highest EV-to-EBIT of ESSA Pharma was 3.00. The lowest was -45.48. And the median was 0.00.

EPIX's EV-to-EBIT is ranked worse than
100% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs EPIX: -4.93

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ESSA Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was $149.73 Mil. ESSA Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.80 Mil. ESSA Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -17.23%.


ESSA Pharma EV-to-EBIT Historical Data

The historical data trend for ESSA Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma EV-to-EBIT Chart

ESSA Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.68 -6.18 -4.27 2.47 0.44

ESSA Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 0.89 1.21 0.44 -5.80

Competitive Comparison of ESSA Pharma's EV-to-EBIT

For the Biotechnology subindustry, ESSA Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ESSA Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's EV-to-EBIT falls into.



ESSA Pharma EV-to-EBIT Calculation

ESSA Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=127.223/-25.798
=-4.93

ESSA Pharma's current Enterprise Value is $127.22 Mil.
ESSA Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ESSA Pharma  (NAS:EPIX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ESSA Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-25.798/149.73442
=-17.23 %

ESSA Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was $149.73 Mil.
ESSA Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ESSA Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ESSA Pharma (ESSA Pharma) Business Description

Traded in Other Exchanges
N/A
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Executives
Peter Virsik officer: Chief Operating Officer 131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson director, officer: Chief Executive Officer C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood officer: Chief Financial Officer 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

ESSA Pharma (ESSA Pharma) Headlines

From GuruFocus

ESSA Pharma to Present at 2022 Jefferies Healthcare Conference

By PRNewswire PRNewswire 07-12-2022